The Law Offices of Frank R. Cruz announces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On May 12, 2026, TriSalus reported first quarter results, including revenue of $8.90M, a decline of 2.92% year over year. The Company further announced a cut to full year revenue guidance to $54 million to $57, a cut of $5.5 million at the midpoint compared to prior guidance.

In the accompanying earnings call, management explained “the driver of this revision includes both the lower Q1 revenues from the commercial expansion and the delayed FDA clearance timing for TriNav Advance.” Management further stated FDA clearance for TriNav Advance “is now running approximately 5 months past the 30-day MDUFA review goal.”

On this, TriSalus’s stock price fell $1.89 per share, or 41.56%, to close at $2.67 on May 13, 2026, thereby injuring investors.